IL124444A0 - Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment - Google Patents

Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment

Info

Publication number
IL124444A0
IL124444A0 IL12444498A IL12444498A IL124444A0 IL 124444 A0 IL124444 A0 IL 124444A0 IL 12444498 A IL12444498 A IL 12444498A IL 12444498 A IL12444498 A IL 12444498A IL 124444 A0 IL124444 A0 IL 124444A0
Authority
IL
Israel
Prior art keywords
predisposition
epilepsy
diagnosis
monitoring
biochemical approach
Prior art date
Application number
IL12444498A
Original Assignee
Svetlana Dolina
Aaron Rabinkov
Eugene Pressman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svetlana Dolina, Aaron Rabinkov, Eugene Pressman filed Critical Svetlana Dolina
Priority to IL12444498A priority Critical patent/IL124444A0/en
Publication of IL124444A0 publication Critical patent/IL124444A0/en
Priority to EP99919514A priority patent/EP1093580A4/en
Priority to CA002332021A priority patent/CA2332021A1/en
Priority to JP2000548720A priority patent/JP2002538412A/en
Priority to PCT/IL1999/000252 priority patent/WO1999058968A1/en
Priority to AU37277/99A priority patent/AU3727799A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12444498A 1998-05-12 1998-05-12 Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment IL124444A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL12444498A IL124444A0 (en) 1998-05-12 1998-05-12 Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
EP99919514A EP1093580A4 (en) 1998-05-12 1999-05-12 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
CA002332021A CA2332021A1 (en) 1998-05-12 1999-05-12 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
JP2000548720A JP2002538412A (en) 1998-05-12 1999-05-12 Diagnosis of epilepsy predisposition and monitoring of antiepileptic treatment
PCT/IL1999/000252 WO1999058968A1 (en) 1998-05-12 1999-05-12 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
AU37277/99A AU3727799A (en) 1998-05-12 1999-05-12 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12444498A IL124444A0 (en) 1998-05-12 1998-05-12 Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment

Publications (1)

Publication Number Publication Date
IL124444A0 true IL124444A0 (en) 1998-12-06

Family

ID=11071485

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12444498A IL124444A0 (en) 1998-05-12 1998-05-12 Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment

Country Status (6)

Country Link
EP (1) EP1093580A4 (en)
JP (1) JP2002538412A (en)
AU (1) AU3727799A (en)
CA (1) CA2332021A1 (en)
IL (1) IL124444A0 (en)
WO (1) WO1999058968A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002329570A1 (en) * 2001-10-12 2003-01-30 Pfizer Products Inc. Method of monitoring neuroprotective treatment
AT9843U1 (en) 2007-03-27 2008-04-15 Kepplinger Berthold Dr MEASUREMENT OF BIOLOGICAL MARKERS
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CA2918447A1 (en) * 2013-07-18 2015-01-22 Dianti Ms Limited Method and prognostic kit for monitoring multiple sclerosis (ms)
KR102699211B1 (en) * 2018-03-19 2024-08-26 후지필름 가부시키가이샤 How to diagnose mental illness
EP3801596A4 (en) * 2018-05-29 2023-01-04 Evogen, Inc. Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures

Also Published As

Publication number Publication date
JP2002538412A (en) 2002-11-12
AU3727799A (en) 1999-11-29
EP1093580A1 (en) 2001-04-25
CA2332021A1 (en) 1999-11-18
EP1093580A4 (en) 2001-09-12
WO1999058968A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
EP1145098A4 (en) System for scheduling and monitoring computer processes
IL128106A0 (en) Non invasive continuous blood glucose monitoring
HUP9901993A3 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
AU2003303597A8 (en) Continuous glucose monitoring system and methods of use
GB2342597B (en) Monitoring of an NOx-storage catalytic converter having an NOx-sensor connected downstream
IL124444A0 (en) Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
GB9807464D0 (en) Purification of human acid µ-glucosidase
HU9602536D0 (en) Treatment of diabetic nephropathy with valsartan
AU2513997A (en) Diagnosis and monitoring of neurological disease
BR9707013A (en) Process for monitoring biological activity of fluids
GB9805913D0 (en) Diagnosis of ms
IL126681A0 (en) Treatment of trauma-related conditions
EP1107778A4 (en) Treatment of disease states
GB9614615D0 (en) Diagnosis of pre-eclampsia
GB9922482D0 (en) Method of diagnosis
AU2002367941A8 (en) Systems and methods for rapid evaluation and design of molecules for predicted biological activity
NZ316343A (en) Diagnosis of nonparaffinophilic microorganisms
GB0116045D0 (en) Monitoring of an nox-storage catalytic converter having an nox-sensor connected downstream
ZA992251B (en) Improved processes for synthesis and purification of nondigestible fats using lipase.
GB9815149D0 (en) Treatment of diabetes
PL313420A1 (en) Method of determining the activity index of active sludge biological processes
IL121656A0 (en) Diagnosis prevention and treatment of diabetes
PL325794A1 (en) Method of illuminating indicating elements and indicating element therefor
GB9621742D0 (en) Diagnosis of diabetes
PL339761A1 (en) Method of obtaining aminocabonylic genezerolin of selective activity against cerebral cholinesterase